Although study results are discrepant, given the beneficial effects on insulin resistance, inflammation, and fibrosis, the administration of exogenous GH for the treatment of secondary GHD NAFLD is justified [57, 61]. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.